GC Green Cross Presents 'Cell Line Development Strategies' at KSBB-AFOB Conference 2025

Establishing an Advanced Cell Line Development Platform Based on Single-Cell Cloning

GC Green Cross announced on the 26th that it gave a presentation on "Cell Line Development for Difficult-to-Express Proteins" at the KSBB-AFOB Conference 2025, held at the Grand Hyatt Incheon in Jung-gu, Incheon, from September 23 to 27.

Kim Yongjae, Head of the EDD Unit at GC Green Cross, is giving a presentation on "Cell Line Development for Difficult-to-Express Proteins" at the KSBB-AFOB Conference 2025 held at the Grand Hyatt Incheon in Jung-gu, Incheon. GC Green Cross

The KSBB-AFOB Conference 2025 is co-hosted by the Korean Society for Biotechnology and Bioengineering (KSBB) and the Asian Federation of Biotechnology (AFOB). This year, under the theme "At the Forefront of Bio-Manufacturing: Shaping a Sustainable Bioeconomy," approximately 3,000 bio experts from industry, academia, research, and government sectors across about 40 countries worldwide attended the event.

Cell lines serve as the "fundamental cells" that produce proteins required for new drug development. Production efficiency and stability are critical factors that determine the success or failure of drug development. However, some proteins have complex structures and low expression levels, making them difficult to produce using conventional methods, which has been a major bottleneck in new drug development. In this presentation, GC Green Cross introduced its cell line development platform designed to address the challenges of producing difficult-to-express proteins (DTEPs).

During the presentation, GC Green Cross highlighted its core strategies: securing homogeneity and stability through single-cell cloning; systematically analyzing and incorporating protein structure, stability, function, and activity at early and final stages; and maximizing process efficiency by utilizing advanced automated equipment such as micro bioreactors.

In particular, the company enhanced its credibility by releasing results from long-term culture stability assessments and protein expression tests of cell lines developed using this platform.

Kim Yongjae, Head of the EDD Unit at GC Green Cross, who delivered the presentation, stated, "Efficient cell line development for difficult-to-express proteins is essential for expanding the biopharmaceutical pipeline," adding, "GC Green Cross will continue to strengthen its competitiveness in the global biopharmaceutical market through its differentiated cell line development platform."

This content was produced with the assistance of AI translation services.